Take a Look at Chemomab Therapeutics (Nasdaq: CMMB) Before Tomorrow Morning

*Sponsored Market Crux Initiates Coverage On Chemomab Therapeutics (Nasdaq: CMMB) Starting Tomorrow Morning—Monday, April /28/2025. And Here’s What We Can Tell You—Tonight. (CMMBC) Comes Backed By Several Potential Catalysts—Including… Analyst Target Set At $7.00 By Maxim Group’s Senior Research Analyst In A Report Published April 25, 2025, Which Suggests Over 430% Upside Potential. Low Float With Fewer Than 17M Shares Could Lead To The Potential For Significant Swings If Demand Begins To Shift. Fresh Technical Momentum With An Approximate 51% Move Over The Past 11 Sessions And Trend Above Key Averages. Positive Regulatory Alignment Secured With FDA For A Streamlined  Phase 3 Trial Design. Take A Look At (CMMB) Before Tomorrow Morning… April 27, 2025 Dear Reader, Every so often, a breakthrough quietly brews just beneath the surface—one that could redefine a forgotten corner of medicine. Picture a patient sitting across from their physician, hearing the words: "There is no approved treatment." Primary Sclerosing Cholangitis (PSC) is one of those rare conditions—a slow, devastating disease where bile ducts become scarred and blocked, leading to liver failure, cancer, and the desperate hope for a transplant.  Despite its severity, no therapies have crossed the finish line.  Until now, perhaps. In the midst of this unmet need, a little-known company—Chemomab Therapeutics (Nasdaq: CMMB)—is racing toward a pivotal moment. With fewer than 17M shares in the float, a market cap under $25M, and a fresh catalyst that could send shockwaves through the market. In a report published just this past Friday, April 25, 2025, it was revealed that Maxim Group’s Senior Research Analyst, Michael Okunewitch, set a $7.00 target on (CMMB)—which suggests 434% upside potential from Friday’s $1.21 close. Momentum has already begun building. Over the past 11 sessions, (CMMB) moved approximately 51%, from $0.8905 on April 10 to $1.35 as of Friday’s close. Technically, (CMMB) is now trending above two key short-term levels: its 5-Day and 20-Day moving averages, currently sitting at $1.2260 and $1.1139, respectively. With the 50-Day, 100-Day, and 200-Day averages clustered above at $1.3413, $1.6346, and $1.5507, the next few sessions could prove critical. According to TradingView’s technical analysis dashboard, (CMMB) was flashing multiple bullish signals as of Friday’s session—an indication that momentum could be quietly building beneath the surface, just as fundamental developments gain traction. Keep reading to see why all eyes will be on (CMMB) heading into Monday morning, April 28, 2025. The Unfolding Story Behind Chemomab Therapeutics’s Momentum… Chemomab Therapeutics (Nasdaq: CMMB) has been building steadily and deliberately—gathering critical clinical evidence and aligning with regulators to advance its lead candidate, Nebokitug, against one of the most stubborn rare liver diseases. Now, a fresh series of developments has brought (CMMB) sharply into focus. On the regulatory front, (CMMB) achieved FDA alignment for a Phase 3 trial focused on real-world clinical events—a streamlined design that avoids the lengthy, invasive approaches often seen in rare disease development. The company is also expanding its scope.  Beyond PSC, (CMMB) is positioning Nebokitug for systemic sclerosis—a rare and aggressive autoimmune disorder that remains an urgent unmet need. Finally, Nebokitug’s five clinical trials showcase a rare trifecta: measurable effects across fibrosis, inflammation, and bile duct dysfunction—an achievement few candidates at this stage can match. With technical signals flashing, regulatory momentum secured, and a differentiated pipeline in motion, (CMMB) may be entering one of the most pivotal stretches in its story yet. Behind the Scenes: A Glimpse Into the Turning Point… On Chemomab Therapeutics (Nasdaq: CMMB)’s latest earnings call, the tone was confident, measured. Executives outlined not just a checklist of achievements, but a strategic roadmap: FDA alignment, Phase 3 readiness, systemic sclerosis expansion, and a ca-sh runway extending into early 2026. One particularly telling moment came when the leadership team described its End-of-Phase 2 meeting—a high-stakes interaction that shaped the company's next chapter.  The FDA's willingness to endorse an event-based trial design was more than a green light; it was a vote of confidence. In rare disease dr-ug development, such moments often separate the contenders from the pretenders. Nebokitug: Targeting the Heart of the Disease… Primary Sclerosing Cholangitis is a disease of chronic inflammation—leading to fibrosis, blockages, and relentless progression. Nebokitug aims directly at the biological pathway responsible: the CCL24 protein. By blocking CCL24, Nebokitug has demonstrated the ability to suppress fibroblast activation, reduce immune cell recruitment, and disrupt the vicious cycle of damage.  In the Phase 2 SPRING trial, patients showed improvements across key markers: liver stiffness, pruritus, and ELF scores. In PSC, these are not just numbers.  They are potential harbingers of slowed disease progression, preserved liver function, and lives changed. Expanding the Vision: Systemic Sclerosis on the Horizon… At the CORA 2025 Conference, Chemomab Therapeutics (Nasdaq: CMMB) revealed new preclinical findings supporting Nebokitug’s mechanism in systemic sclerosis. In this aggressive autoimmune disorder, fibrosis spreads mercilessly through skin and lungs.  Elevated CCL24 levels have been strongly linked to disease severity, and in laboratory models, blocking this pathway led to a reduction in fibrosis markers and inflammation. With a Phase 2-ready program and regulatory groundwork already laid, (CMMB) could soon extend its reach beyond PSC—targeting two high-need rare diseases with a single, differentiated therapeutic approach. The Bigger Picture: A Market Ripe for Disruption… The liver fibrosis treatment market alone is projected to more than double, from $20.35B in 2025 to $52.26B by 2034.  In the U.S. alone, growth from $5.41B to $14.18B is expected over the same period. Yet in PSC, the market remains wide open.  No approved therapies.  No dominant players.  No blueprint to follow—until now. Chemomab's disciplined progress, low-float share structure, and potential to impact two major rare disease spaces place it at a crossroads that few have yet noticed. Looking Ahead: A Name to Watch Closely… Chemomab Therapeutics (Nasdaq: CMMB) stands at a threshold. A Phase 3-ready asset.  Regulator-endorsed trial design. A second rare disease program within reach.  Clinical data already signaling biological impact. As final protocol lock nears and the pivotal trial launches, Chemomab may no longer stay under the radar for long. We encourage all readers to follow this one closely tomorrow morning. 7 Reasons Why Chemomab Therapeutics (Nasdaq: CMMB) Will Be Topping Our Watchlist Tomorrow Morning—Monday, April 28, 2025… 1. Low Float Structure: With fewer than 17M shares floating, (CMMB) remains tightly held, a characteristic that can heighten sensitivity to catalysts. 2. Fresh Technical Momentum: Over the past 11 sessions, (CMMB) moved approximately 51%, from $0.8905 on April 10 to $1.35 as of Friday’s close, and is now trending above key short-term averages. 3. Analyst Target: In a report published on April 25, 2025, Maxim Group’s Senior Research Analyst set a $7.00 target on (CMMB), which suggests over 430% upside potential from Friday’s close. 4. Positive Regulatory Alignment: (CMMB) has secured FDA agreement on a Phase 3 trial design using real-world clinical event endpoints, streamlining the pathway ahead in a space with no approved treatments. 5. Pipeline Expansion: Beyond Primary Sclerosing Cholangitis (PSC), (CMMB) is advancing its program into systemic sclerosis, backed by strong preclinical validation. 6. Biomarker-Driven Validation: Nebokitug has shown measurable improvements across fibrosis, inflammation, and bile duct function—key drivers in rare fibro-inflammatory diseases. 7. Positioning in a Rapidly Growing Market: The liver fibrosis treatment market is projected to more than double by 2034, with substantial unmet need in both PSC and systemic sclerosis creating a wide-open landscape for innovation. Take a Look at (CMMB) Before Tomorrow Morning… Chemomab Therapeutics (CMMB) is stepping into a critical stretch of its development cycle, supported by a tightly held float, accelerating technical momentum, and a regulatory pathway now clearly defined.  With a recently issued $7.00 target from Maxim Group and expanding validation across two rare disease areas, this is a company that continues to sharpen its profile. The combination of scientific validation, market positioning, and recent movement could set the stage for an active period ahead. We will have all eyes on (CMMB) tomorrow morning. Consider taking a look at (CMMB) before you call it a night. Also, keep a lookout for my morning update. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 04/27/2025 and ending on 04/28/2025 to publicly disseminate information about (CMMB:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (CMMB:US). Please see important disclosure information here: https://marketcrux.com/disclosure/cmmb-zuhml/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice